Atatürk Üniversitesi Atatürk Üniversitesi
Ara
Yayınlara dön
Makale Tam Makale Uluslararası 2012

Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology)

Muhammet Ali Kaplan, Abdurrahman Isikdogan, Dogan Koca, Mehmet Kucukoner, Ozge Gumusay, Ramazan Yildiz, Adem Dayan, Lutfiye Demir, Caglayan Geredeli, Murat Kocer, Ulku Yalcintas Arslan, Ali Inal, Olcun Umit Unal, Aslihan Guven Mert, Mehmet Bilici, METİN ÖZKAN, EMİN TAMER ELKIRAN, Sebnem Yaman, Ayse Gok Durnali, Ali Suner, Suleyman Alici, Mustafa Oktay Tarhan, Cem Boruban, Zuhat Urakci, Suleyman Buyukberber

ONCOLOGY Cilt 83 · Sayı 3 · ss. 141–150 · 01.01.2012
DOI ile aç

Özet

Background: The aim of this study is to determine the relationship between the survival outcomes and biological subtype in breast cancer patients with brain metastases. Methods: We retrospectively evaluated clinical data from 422 breast cancer patients with brain metastases between 2001 and 2011 from referral centers in Turkey. The study population was divided into four biological subtypes according to their hormone receptor status and HER2 expression. Results: Systemic treatment prolonged median overall survival (OS) after brain metastases in the entire group (14 vs. 3.2 months, p < 0.001). It also prolonged median OS after brain metastases in the triple negative (7.5 vs. 1.6 months, p = 0.010) and luminal A (14.3 vs. 7.1 months, p = 0.003) subgroups. The median OS for untreated patients, chemotherapy and/or hormonal therapy receiving patients, and chemotherapy and/or hormonal therapy plus targeted therapy receivers was 2, 5.8, and 17.7 months, respectively (p < 0.001), in the HER2-overexpressing subgroup. In the luminal B subgroup, it was 3.7, 5.3, and 15.4 months, respectively (p = 0.003). Conclusions: The use of systemic therapy improves OS after brain metastases in all biological subgroups. Targeted therapies also improve OS after brain metastases in HER2-positive patients. The combined use of targeted therapies and lapatinib are superior to single use and trastuzumab, respectively, in these patients. Copyright (C) 2012 S. Karger AG, Basel

Anahtar kelimeler

Breast cancer Brain metastasis Biological subtype

Sürdürülebilir Kalkınma Amaçları

  • SKA 3: Sağlıklı Bireyler

Atıf için künye

Kaplan, M. A., Isikdogan, A., Koca, D., Kucukoner, M., Gumusay, O., Yildiz, R., Dayan, A., Demir, L., Geredeli, C., Kocer, M., Arslan, U. Y., Inal, A., Unal, O. U., Mert, A. G., Bilici, M., ÖZKAN, M., ELKIRAN, E. T., Yaman, S., Durnali, A. G., … Buyukberber, S. (2012). Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology). ONCOLOGY, 83(3), 141–150. https://doi.org/10.1159/000338782

BibTeX 
@article{kaplan2012-228387,
  author = {Kaplan, Muhammet Ali and Isikdogan, Abdurrahman and Koca, Dogan and Kucukoner, Mehmet and Gumusay, Ozge and Yildiz, Ramazan and Dayan, Adem and Demir, Lutfiye and Geredeli, Caglayan and Kocer, Murat and Arslan, Ulku Yalcintas and Inal, Ali and Unal, Olcun Umit and Mert, Aslihan Guven and Bilici, Mehmet and ÖZKAN, METİN and ELKIRAN, EMİN TAMER and Yaman, Sebnem and Durnali, Ayse Gok and Suner, Ali and Alici, Suleyman and Tarhan, Mustafa Oktay and Boruban, Cem and Urakci, Zuhat and Buyukberber, Suleyman},
  title = {Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology)},
  journal = {ONCOLOGY},
  year = {2012},
  volume = {83},
  number = {3},
  pages = {141--150},
  issn = {0030-2414},
  doi = {10.1159/000338782},
  url = {https://akademik.atauni.edu.tr/yayinlar/228387-biological-subtypes-and-survival-outcomes-in-breast-cancer-patients-with-brain}
}